Geode Capital Management, LLC Phathom Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 862,918 shares of PHAT stock, worth $7.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

862,918

Previous 806,047 7.06%

Holding current value

$7.71 Million

Previous $8.3 Million 87.92%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.25 - $19.5 $582,927 - $1.11 Million	56,871 Added 7.06%	862,918 $15.6 Million
Q2 2024 Aug 09, 2024	BUY	$8.97 - $12.05 $490,371 - $658,749	54,668 Added 7.28%	806,047 $8.3 Million
Q1 2024 May 13, 2024	BUY	$6.21 - $11.05 $100,018 - $177,971	16,106 Added 2.19%	751,379 $7.98 Million
Q4 2023 Feb 13, 2024	BUY	$6.99 - $10.71 $368,393 - $564,449	52,703 Added 7.72%	735,273 $6.71 Million
Q3 2023 Nov 13, 2023	BUY	$10.26 - $15.7 $1.97 Million - $3.02 Million	192,447 Added 39.27%	682,570 $7.08 Million
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $302,207 - $594,451	41,512 Added 9.25%	490,123 $7.02 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $83,979 - $167,688	13,567 Added 3.12%	448,611 $3.2 Million
Q4 2022 Feb 13, 2023	BUY	$9.18 - $11.53 $300,663 - $377,630	32,752 Added 8.14%	435,044 $4.88 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $357,599 - $670,361	55,356 Added 15.96%	402,292 $4.46 Million
Q2 2022 Aug 12, 2022	BUY	$6.2 - $15.5 $205,337 - $513,344	33,119 Added 10.55%	346,936 $2.93 Million
Q1 2022 May 13, 2022	BUY	$11.55 - $20.06 $238,149 - $413,617	20,619 Added 7.03%	313,817 $4.27 Million
Q4 2021 Feb 11, 2022	BUY	$17.83 - $33.15 $166,443 - $309,455	9,335 Added 3.29%	293,198 $5.77 Million
Q3 2021 Nov 12, 2021	BUY	$30.69 - $36.83 $76,418 - $91,706	2,490 Added 0.88%	283,863 $9.11 Million
Q2 2021 Aug 13, 2021	BUY	$32.66 - $39.87 $2.35 Million - $2.87 Million	71,865 Added 34.3%	281,373 $9.52 Million
Q1 2021 May 12, 2021	BUY	$33.86 - $48.68 $1.08 Million - $1.56 Million	32,034 Added 18.05%	209,508 $7.87 Million
Q4 2020 Feb 12, 2021	SELL	$33.22 - $50.26 $137,032 - $207,322	-4,125 Reduced 2.27%	177,474 $5.9 Million
Q3 2020 Nov 13, 2020	BUY	$29.24 - $40.19 $95,234 - $130,898	3,257 Added 1.83%	181,599 $6.66 Million
Q2 2020 Aug 13, 2020	BUY	$25.06 - $54.6 $436,419 - $950,859	17,415 Added 10.82%	178,342 $5.87 Million
Q1 2020 May 14, 2020	BUY	$24.65 - $42.83 $184,702 - $320,925	7,493 Added 4.88%	160,927 $4.16 Million
Q4 2019 Feb 13, 2020	BUY	$18.59 - $37.67 $2.85 Million - $5.78 Million	153,434 New	153,434 $4.78 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $350M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Phathom Pharmaceuticals, Inc. Transaction History